|
1
|
Huang J, Wu S, Barrera J, Matthews K and
Pan D: The Hippo signaling pathway coordinately regulates cell
proliferation and apoptosis by inactivating Yorkie, the Drosophila
homolog of YAP. Cell. 122:421–434. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hilman D and Gat U: The evolutionary
history of YAP and the Hippo/YAP pathway. Mol Biol Evol.
28:2403–2417. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu FX and Guan KL: The Hippo pathway:
Regulators and regulations. Genes Dev. 27:355–371. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zeng Q and Hong W: The emerging role of
the Hippo pathway in cell contact inhibition, organ size control
and cancer development in mammals. Cancer Cell. 13:188–192. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Halder G and Johnson RL: Hippo signaling:
Growth control and beyond. Development. 138:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oh H and Irvine KD: Yorkie: The final
destination of Hippo signaling. Trends Cell Biol. 20:410–417. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schlegelmilch K, Mohseni M, Kirak O,
Pruszak J, Rodriguez JR, Zhou D, Kreger BT, Vasioukhin V, Avruch J,
Brummelkamp TR and Camargo FD: YAP1 acts downstream of α-catenin to
control epidermal proliferation. Cell. 144:782–795. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang J, Ji JY, Yu M, Overholtzer M,
Smolen GA, Wang R, Brugge JS, Dyson NJ and Haber DA: YAP-dependent
induction of amphiregulin identifies a non-cell-autonomous
component of the Hippo pathway. Nat Cell Biol. 11:1444–1450. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Strano S and Blandino G: YAP1 meets tumor
suppression. Mol Cell. 27:863–864. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Farazi PA and Depinho RA: Hepatocellular
carcinoma pathogenesis: From genes to environment. Nat Rev Cancer.
6:674–687. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dong J, Feldmann G, Huang J, Wu S, Zhang
N, Comerford SA, Gayyed MF, Anders RA, Maitra A and Pan D:
Elucidation of a universal size-control mechanism in drosophila and
mammals. Cell. 130:1120–1133. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang J, Ma L, Weng W, Qiao Y, Zhang Y, He
J, Wang H, Xiao W, Li L, Chu Q, et al: Mutual interaction between
YAP and CREB promotes tumorigenesis in liver cancer. Hepatology.
58:1011–1020. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tang X, Chen X, Xu Y, Qiao Y, Zhang X,
Wang Y, Guan Y, Sun F and Wang J: CD166 positively regulates MCAM
via inhibition to ubiquitin E3 ligases Smurf1 and βTrCP through
PI3K/AKT and c-Raf/MEK/ERK signaling in Bel-7402 hepatocellular
carcinoma cells. Cell Signal. 27:1694–1702. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Y, Fang R, Cui M, Zhang W, Bai X,
Wang H, Liu B, Zhang X and Ye L: The oncoprotein HBXIP up-regulates
YAP through activation of transcription factor c-Myb to promote
growth of liver cancer. Cancer Lett. 385:234–242. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu G, Wang J, Wu F, Wang N, Zhou W, Wang
Q, Pan W, Ao G and Yang J: YAP and 14–3-3γ are involved in
HS-OA-induced growth inhibition of hepatocellular carcinoma cells:
A novel mechanism for hydrogen sulfide releasing oleanolic acid.
Oncotarget. 7:52150–52165. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Perra A, Kowalik MA, Ghiso E,
Ledda-Columbano GM, Di Tommaso L, Angioni MM, Raschioni C, Testore
E, Roncalli M, Giordano S and Columbano A: YAP activation is an
early event and a potential therapeutic target in liver cancer
development. J Hepatol. 61:1088–1096. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Loforese G, Malinka T, Keogh A, Baier F,
Simillion C, Montani M, Halazonetis TD, Candinas D and Stroka D:
Impaired liver regeneration in aged mice can be rescued by
silencing Hippo core kinases MST1 and MST2. EMBO Mol Med. 9:46–60.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yi J, Lu L, Yanger K, Wang W, Sohn BH,
Stanger BZ, Zhang M, Martin JF, Ajani JA, Chen J, et al: Large
tumor suppressor homologs 1 and 2 regulate mouse liver progenitor
cell proliferation and maturation through antagonism of the
coactivators YAP and TAZ. Hepatology. 64:1757–1772. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Perumal N, Perumal M, Kannan A, Subramani
K, Halagowder D and Sivasithamparam N: Morin impedes Yap nuclear
translocation and fosters apoptosis through suppression of
Wnt/β-catenin and NF-κB signaling in Mst1 overexpressed HepG2
cells. Exp Cell Res. 355:124–141. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang J, Park J, Wei Y, Rajurkar M, Cotton
JL, Fan Q, Lewis BC, Ji H and Mao J: TRIB2 acts downstream of
Wnt/TCF in liver cancer cells to regulate YAP and C/EBPα function.
Mol Cell. 51:211–225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang YP and Tang DX: Expression of
Yes-associated protein in liver cancer and its correlation with
clinicopathological features and prognosis of liver cancer
patients. Int J Clin Exp Med. 8:1080–1086. 2015.PubMed/NCBI
|
|
22
|
Tordjmann T: Hippo signaling: Liver size
regulation and beyond. Clin Res Hepatol Gastroenterol. 35:344–346.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT,
Zender L, Lowe SW, Poon RT and Luk JM: Yes-associated protein is an
independent prognostic marker in hepatocellular carcinoma. Cancer.
115:4576–4585. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zender L, Spector MS, Xue W, Flemming P,
Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et
al: Idetification and validation of oncogenes in liver cancer using
an integrative oncogenomic approach. Cell. 125:1253–1267. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu
J, Lin JD, Wang CY, Chinnaiyan AM, et al: TEAD mediates
YAP-dependent gene induction and growth control. Genes Dev.
22:1962–1971. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cai WY, Lin LY, Hao H, Zhang SM, Ma F,
Hong XX, Zhang H, Liu QF, Ye GD, Sun GB, et al: Yes-associated
protein/TEA domain family member and hepatocyte nuclear factor
4-alpha (HNF4α) repress reciprocally to regulate
hepatocarcinogenesis in rats and mice. Hepatology. 65:1206–1221.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin C, Hu Z, Lei B, Tang B, Yu H, Qiu X
and He S: Overexpression of Yes-associated protein and its
association with clinicopathological features of hepatocellular
carcinoma: A meta-analysis. Liver Int. Mar 26–2017.(Epub ahead of
print). View Article : Google Scholar
|
|
28
|
Song Y, Kim SH, Kim KM, Choi EK, Kim J and
Seo HR: Activated hepatic stellate cells play pivotal roles in
hepatocellular carcinoma cell chemoresistance and migration in
multicellular tumor spheroids. Sci Rep. 6:367502016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mannaerts I, Leite SB, Verhulst S,
Claerhout S, Eysackers N, Thoen LF, Hoorens A, Reynaert H, Halder G
and van Grunsven LA: The Hippo pathway effector YAP controls mouse
hepatic stellate cell activation. J Hepatol. 63:679–688. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Paget S: The distribution of secondary
growths in cancer of the breast. 1989. Cancer Metastasis Rev.
8:98–101. 1989.PubMed/NCBI
|
|
31
|
Okabe H, Beppu T, Hayashi H, Horino K,
Masuda T, Komori H, Ishikawa S, Watanabe M, Takamori H, Iyama K and
Baba H: Hepatic stellate cells may relate to progression of
intrahepatic cholangiocarcinoma. Ann Surg Oncol. 16:2555–2564.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lian I, Kim J, Okazawa H, Zhao J, Zhao B,
Yu J, Chinnaiyan A, Israel MA, Goldstein LS, Abujarour R, et al:
The role of YAP transcription coactivator in regulating stem cell
self-renewal and differentiation. Genes Dev. 24:1106–1118. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma L, Lin J, Qiao Y, Weng W, Liu W, Wang J
and Sun F: Serum CD166: A novel hepatocellular carcinoma tumor
marker. Clin Chim Acta. 441:156–162. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang J, Tang X, Weng W, Qiao Y, Lin J, Liu
W, Liu R, Ma L, Yu W, Yu Y, et al: The membrane protein melanoma
cell adhesion molecule (MCAM) is a novel tumor marker that
stimulates tumorigenesis in hepatocellular carcinoma. Oncogene.
36:5781–5795. 2015. View Article : Google Scholar
|
|
35
|
Camargo FD, Gokhale S, Johnnidis JB, Fu D,
Bell GW, Jaenisch R and Brummelkamp TR: YAP1 increases organ size
and expands undifferentiated progenitor cells. Curr Bio1.
17:2054–2060. 2007. View Article : Google Scholar
|
|
36
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu AM, Xu MZ, Chen J, Poon RT and Luk JM:
Targeting YAP and Hippo signaling pathway in liver cancer. Expert
Opin Ther Targets. 14:855–868. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou D, Conrad C, Xia F, Park JS, Payer B,
Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J and Bardeesy N: Mst1
and Mst2 maintain hepatocyte quiescence and sup-press
hepatocellular carcinoma development through inac-tivation of the
Yap1 oncogene. Cancer Cell. 16:425–438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu AM, Poon RT and Luk JM: MicroRNA-375
targets Hippo-signaling effector YAP in liver cancer and inhibits
tumor properties. Biochem Biophys Res Commun. 394:623–627. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang Y, Cui M, Sun BD, Liu FB, Zhang XD
and Ye LH: miR-506 suppresses proliferation of hepatoma cells
through targeting YAP mRNA 3′UTR. Acta Pharmacol Sin. 35:1207–1214.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bai N, Zhang C, Liang N, Zhang Z, Chang A,
Yin J, Li Z, Luo N, Tan X, Luo N, et al: Yes-associated protein
(YAP) increases chemosensitivity of hepatocellular carcinoma cells
by modulation of p53. Cancer Biol Ther. 14:511–520. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang W and Cohen SM: The Hippo pathway
acts via p53 and microRNAs to control proliferation and
proapoptotic gene expression during tissue growth. Biol Open.
2:822–828. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shimizu D, Inokawa Y, Sonohara F, Inaoka K
and Nomoto S: Search for useful biomarkers in hepatocellular
carcinoma, tumor factors and background liver factors (Review).
Oncol Rep. 37:2527–2542. 2017.PubMed/NCBI
|
|
44
|
Noubissi FK, Elcheva I, Bhatia N, Shakoori
A, Ougolkov A, Liu J, Minamoto T, Ross J, Fuchs SY and Spiegelman
VS: CRD-BP mediates stabilization of betaTrCP1 and c-myc mRNA in
response to beta-catenin signalling. Nature. 441:898–901. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Thompson MD and Monga SP: Wnt/beta-catenin
signaling in liver health and disease. Hepatology. 45:1298–1305.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Qiao Y, Zhang Y and Wang J: Ubiquitin E3
ligase SCF(β-TRCP) regulates TRIB2 stability in liver cancer cells.
Biochem Biophys Res Commun. 441:555–559. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xiao W, Wang J, Ou C, Zhang Y, Ma L, Weng
W, Pan Q and Sun F: Mutual interaction between YAP and c-Myc is
critical for carcinogenesis in liver cancer. Biochem Biophys Res
Commun. 439:167–172. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xu Y, Stamenkovic I and Yu Q: CD44
attenuates activation of the Hippo signaling pathway and is a prime
therapeutic target for glioblastoma. Cancer Res. 70:2455–2464.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fernandez LA, Northcott PA, Dalton J,
Fraga C, Ellison D, Angers S, Taylor MD and Kenney AM: YAP1 is
amplified and upregulated in hedgehog-associated medulloblastomas
and mediates Sonic hedgehog-driven neural precursor proliferation.
Genes Dev. 23:2729–2741. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yu JZ, Poulton J, Huang YC and Deng WM:
The hippo pathway promotes Notch signaling in regulation of cell
differentiation, proliferation, and oocyte polarity. PLoS One.
3:e17612008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kim D, Shu S, Coppola MD, Kaneko S, Yuan
ZQ and Cheng JQ: Regulation of proapoptotic mammalian ste20-like
kinase MST2 by the IGF1-Akt pathway. PLoS One. 5:e96162010.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yuan Z, Kim D, Shu S, Wu J, Guo J, Xiao L,
Kaneko S, Coppola D and Cheng JQ: Phosphoinositide 3-kinase/Akt
inhibits MST1-mediated pro-apoptotic signaling through
phosphorylation of threonine 120. J Biol Chem. 285:3815–3824. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Joliat GR, Allemann P, Labgaa I,
Demartines N and Halkic N: Treatment and outcomes of recurrent
hepatocellular carcinomas. Langenbecks Arch Surg. May 11–2017.(Epub
ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tu K, Yang W, Li C, Zheng X, Lu Z, Guo C,
Yao Y and Liu Q: Fbxw7 is an independent prognostic marker and
induces apoptosis and growth arrest by regulating YAP abundance in
hepatocellular carcinoma. Mol Cancer. 13:1102014. View Article : Google Scholar : PubMed/NCBI
|
